“…Takemura et al leverage a robust, well-annotated, retrospective database to explore the real-world experience of patients exhibiting complete response (CR) to frontline therapy in mRCC, including those who received combination ICI agents. 2 Compared to the landmark trials leading to Food and Drug Administration approval of these ICI combinations, the authors report remarkably lower CR rates using these drugs. The heterogeneity in the International Metastatic Renal Cell Carcinoma Database Consortium database—such as variability in the type and duration of treatment received and baseline clinicopathological characteristics—is an important surrogate for the real-world experience and may help guide oncologists in counseling patients with mRCC.…”